Related Experiment Video
Updated: Jun 25, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
Automated Insulin Delivery Systems in Pediatric Type 1 Diabetes: A Narrative Review
Peter Adolfsson1,2, Ragnar Hanas1,3, Dessi P Zaharieva4
1Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Journal of Diabetes Science and Technology
|May 24, 2024
Summary
Automated insulin delivery (AID) systems offer new ways to manage type 1 diabetes in children. This review explores current AID technology, challenges, and future advancements for pediatric diabetes care.
Area of Science:
- Pediatric Endocrinology
- Biomedical Engineering
- Diabetes Technology
Background:
- Type 1 diabetes management in children presents unique challenges.
- Automated Insulin Delivery (AID) systems represent a significant advancement in diabetes care.
- Current AID systems vary in features and algorithms, impacting their clinical application.
Purpose of the Study:
- To review the current landscape of AID systems for pediatric type 1 diabetes.
- To identify challenges and opportunities for AID system advancement in this population.
- To provide expert insights on adapting AID systems to dynamic glycemic conditions.
Main Methods:
- Narrative review of existing research on AID systems.
- Analysis of differences between commercially available AID systems.
- Inclusion of expert opinions and case examples.
Main Results:
- AID systems show promise in managing pediatric type 1 diabetes.
- Challenges include system variability and adapting to rapid insulin needs (e.g., illness, exercise).
- Case descriptions illustrate user-initiated actions and alternative AID system applications.
Conclusions:
- AID systems are evolving tools for pediatric type 1 diabetes management.
- Further research and system development are needed to optimize AID use.
- Expert guidance is crucial for navigating complex glycemic scenarios with AID.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
167
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
167
01:27Insulin Formulations: Types and Delivery
191
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
191
01:22Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
373
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
373
01:15Diabetes: Management and Pharmacotherapy
265
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
265
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K